Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Oncology
ASCO 2024 - Chris Haqq interview with Jonah Comstock

ASCO 2024 - Chris Haqq

ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share encouraging early-stage results, especially those that point to a new p

Oncology
ASCO 2024 - Steve Devine interview with Jonah Comstock

ASCO 2024 - Steve Devine

While advances in cell and gene therapies chip away at the need for bone marrow transplants, the transplantation field remains very much alive and in the midst of innovations of its own.

Sales & Marketing

Digital

Market Access

Market Access
Mumbai, India

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

Editor's Picks

  1. Revolution's ASCO showstopper gets FDA greenlight
  2. Anthropic AI tool conducts physical scientific experiments
  3. UK MHRA authorises orforglipron private prescription
  4. Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
  5. Sword Health buys Headspace in $200m to $300m deal

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

more

Patients

more

R&D

more